Hypertension in Adults: Diagnostic and Treatment Approach
For adults with hypertension, implement team-based care with home blood pressure monitoring (HBPM) using the 722 protocol (duplicate readings, twice daily, over 7 days), define hypertension as ≥130/80 mm Hg, and initiate treatment with a target BP <130/80 mm Hg for all adults, starting with combination therapy (single-pill fixed-dose combination of 2 first-line agents) for stage 2 hypertension (≥140/90 mm Hg). 1, 2
Blood Pressure Classification and Diagnosis
The 2025 AHA/ACC guidelines establish clear BP categories 2:
- Normal BP: <120/<80 mm Hg
- Elevated BP: 120-129/<80 mm Hg
- Stage 1 Hypertension: 130-139/80-89 mm Hg
- Stage 2 Hypertension: ≥140/≥90 mm Hg
Measurement Protocol
Use automated oscillometric upper-arm cuff devices that have been properly validated 3. Office measurements alone are insufficient—confirm diagnosis with out-of-office monitoring using either:
- Home BP Monitoring (HBPM) - preferred method using the 722 protocol: duplicate readings per occasion, twice daily (morning and evening), over 7 consecutive days 4
- 24-hour Ambulatory BP Monitoring (ABPM) - alternative confirmation method 3
This approach addresses the critical limitation that office BP measurements are unreliable in real-world practice and poorly correlate with target organ damage compared to HBPM 4.
Treatment Initiation Algorithm
When to Start Medication
Immediate pharmacotherapy (in addition to lifestyle modification) for 2:
- Average BP ≥140/90 mm Hg (all adults)
- Average BP ≥130/80 mm Hg with any of:
- Clinical cardiovascular disease
- Previous stroke
- Diabetes mellitus
- Chronic kidney disease
- 10-year PREVENT cardiovascular risk ≥7.5%
Delayed pharmacotherapy for BP 130-139/80-89 mm Hg with PREVENT risk <7.5%: trial lifestyle modification for 3-6 months first; if BP remains ≥130/80 mm Hg, initiate medication 2
Medication Selection
For Stage 2 Hypertension (≥140/90 mm Hg): Start with 2 first-line agents in a single-pill fixed-dose combination (preferred over separate pills for better adherence and faster control) 2
First-line agents (all equally acceptable) 2, 4:
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin receptor blockers (ARBs)
- Calcium channel blockers (CCBs)
- Thiazide diuretics
- Beta-blockers
For Stage 1 Hypertension (130-139/80-89 mm Hg): May start with single agent, but combination therapy is reasonable if BP is ≥20/10 mm Hg above target 4
Lifestyle Interventions (All Patients)
Strongly recommended for all adults with elevated BP or hypertension 2:
- DASH (Dietary Approaches to Stop Hypertension) eating pattern
- Sodium restriction (<2,300 mg/day, ideally <1,500 mg/day)
- Increased dietary potassium intake
- Weight loss if overweight (target healthy BMI)
- Regular moderate physical activity (150 minutes/week aerobic exercise)
- Stress management
- Alcohol reduction or elimination
These interventions are not optional add-ons but foundational therapy that must be implemented alongside medication.
Team-Based Care Model
Assemble a multidisciplinary team including 1, 2:
- Primary care clinicians
- Pharmacists (medication management, adherence)
- Nurses/nurse practitioners (BP monitoring, patient education)
- Dieticians (dietary counseling)
- Community health workers (addressing social determinants)
Team-based care is a Class 1, Level A recommendation—the strongest evidence grade—demonstrating significant improvements in BP control rates 1. This model addresses medication access barriers, structural obstacles, and social determinants of health that impede hypertension control.
Follow-Up and Monitoring Strategy
Monthly follow-up is required for patients on new or intensified therapy until BP control is achieved 1. Each visit should assess:
- Medication adherence
- Response to treatment (review HBPM readings)
- Adverse effects
- Barriers to care
Integrate health information technology: Use telehealth (synchronous or asynchronous), electronic health records, and patient registries to improve access, adherence, and identification of uncontrolled patients 1. Telehealth interventions have Class 2a, Level B-R evidence for reducing BP and improving control rates 1.
Target Hierarchy for Optimization
Follow this sequence 4:
- Achieve HBPM target (<130/80 mm Hg)
- Assess hypertension-mediated organ damage (HMOD) - ensure stable or regressed
- Consider ABPM if targets not met or HMOD progressing despite apparent control
Critical Pitfalls to Avoid
Do not rely on cuffless devices (smartwatches) for BP measurements—they lack precision and reliability 2. This is a common error as these devices become more prevalent.
Do not use office BP alone for treatment decisions—this leads to misclassification and poor outcomes 4, 3.
Do not delay combination therapy in stage 2 hypertension—monotherapy prolongs time to control and increases cardiovascular risk 2.
Severe hypertension (>180/120 mm Hg) without acute target organ damage should be managed in the outpatient setting with oral medications, not the emergency department 2. Initiate, reinstitute, or intensify therapy promptly but avoid precipitous BP reduction.
Special Consideration: Universal BP Target
The 2025 guidelines establish <130/80 mm Hg as the universal target for all adults, with additional considerations only for those requiring institutional care, having limited predicted lifespan, or who are pregnant 2. This represents a paradigm shift from the historical 140/90 mm Hg threshold, supported by major trials (SPRINT, STEP) demonstrating cardiovascular benefit at lower targets 4.